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Abstract
Background: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be
successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial
proportion of patients after the apparent success. No laboratory markers are known that are predictive of cART outcome in
initial responders during the period of undetectable plasma viremia.
Methodology/Principal Findings: Here, we report the results of a retrospective longitudinal study of twenty-six HIV-
infected individuals who initially responded to cART by having plasma viremia suppressed to ,50 copies/ml. Eleven of
these patients remained virologically suppressed, whereas fifteen experienced subsequent cART failure. Using sensitive
methods based on seminested real-time PCR, we measured the levels of HIV-1 proviral (pr) DNA, unspliced (us) RNA, and
multiply spliced RNA in the peripheral blood mononuclear cells (PBMC) of these patients at multiple time points during the
period of undetectable plasma viremia on cART. Median under-therapy level of usRNA was significantly higher (0.43 log10
difference, P=0.0015) in patients who experienced subsequent cART failure than in successfully treated patients. In
multivariate analysis, adjusted for baseline CD4
+ counts, prior ART experience, and particular cART regimens, the maximal
usRNA level under therapy was the best independent predictor of subsequent therapy failure (adjusted odds ratio [95% CI],
24.4 [1.5–389.5], P=0.024). The only other factor significantly associated with cART failure was prior ART experience
(adjusted odds ratio [95% CI], 12.3 [1.1–138.4], P=0.042). Levels of usRNA under cART inversely correlated with baseline
CD4
+ counts (P=0.0003), but did not correlate with either baseline usRNA levels or levels of prDNA under therapy.
Conclusion: Our data demonstrate that the level of HIV-1 usRNA in PBMC, measured in cART-treated patients with
undetectable plasma viremia, is a strong predictive marker for the outcome of therapy.
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Introduction
Combination antiretroviral therapy (cART), the standard of
care for human immunodeficiency virus type 1 (HIV-1) infection
[1–3], is an exemplary success of modern medicine, as it has
resulted in a dramatic decrease in HIV-related morbidity and
mortality [4,5]. Since the introduction of cART, the response to
therapy has dramatically improved, with currently most patients
reaching HIV RNA levels in plasma that are below the limit of
detection of modern commercial assays (,50 copies/ml). Despite
these encouraging results, failure of ART is still a common
problem. In the Netherlands, the annual proportion of previously
therapy-naı ¨ve patients who experience failure increased from 6%
to 9% in the period between 1997 and 2007 (F. de Wolf. The HIV
epidemic in the Netherlands. The 2nd Netherlands Conference on
HIV Pathogenesis, Prevention and Treatment, 25 November
2008, Amsterdam, The Netherlands).
In initial cART responders, previous ART experience and
specific drug regimens are associated with subsequent therapy
failure (virological rebound, VR) [6–11]. In addition, several
baseline parameters (plasma HIV-1 viremia, CD4
+ counts, HIV-1
DNA level in PBMC) were reported to be associated with the risk
of VR [6,12,13]. However, no laboratory markers have yet been
identified that are predictive of cART outcome in initial
responders during the period of undetectable plasma viremia.
Whether HIV-1 continues to replicate in patients on cART is a
matter of considerable debate [14–26]. The best evidence for
residual HIV-1 replication comes from the studies on viral
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8490evolution [17,18,20,22], which demonstrated patient-specific
differences in HIV-1 evolution under cART. If residual viral
replication continues in some patients on cART but not in others,
the former are more prone to develop drug-resistance mutations
and, as a consequence, fail therapy. Hence, quantifying the levels
of intracellular HIV-1 RNA and DNA in patients on cART could
provide hints as to why some patients fail therapy.
We have recently developed sensitive seminested real-time PCR
methods based on TaqMan chemistry for quantitation of
intracellular HIV-1 proviral (pr) DNA and both unspliced (us)
and multiply spliced (ms) RNA forms [27]. Using these methods,
we have recently demonstrated a singnificant longitudinal increase
in levels of usRNA in PBMC of the majority of untreated patients
with steady-state plasma RNA loads in the asymptomatic phase of
HIV-1 infection (Pasternak et al., manuscript in preparation). This
finding indicates that in untreated patients, HIV-1 usRNA load in
PBMC may be a more sensitive prognostic indicator than viral
RNA load in plasma. Here, we used these methods to study the
predictive value of intracellular levels of viral RNA and DNA for
the virological outcome of therapy.
Results
Cellular HIV-1 load (prDNA, usRNA, and msRNA) was
quantified in PBMC at baseline and at multiple time points during
the period of undetectable HIV-1 plasma viremia on cART (‘‘the
eclipse phase’’) in patients who were successfully treated with
cART (‘‘successes’’) and those who experienced VR on cART
after achieving undetectable HIV-1 load in plasma (‘‘failures’’).
UsRNA and prDNA were detected and quantified in all baseline
PBMC samples and in 94% of the under-therapy PBMC samples.
MsRNA could be detected and quantified in 83% of the baseline
samples, but only in 16% of the under-therapy samples (Table S1),
precluding any quantitative comparison of msRNA levels under
cART between the patient groups. To account for the possible
effects of mismatches in the primer and probe binding regions on
the efficiency of real-time PCR, all quantified amounts of prDNA
and usRNA in the baseline and under-therapy PBMC samples
were normalized to the individual mismatch-related quantification
errors (see Methods and Figure S1).
None of the baseline characteristics, except for prior ART
experience (P=0.015) and baseline CD4
+ count (P=0.019), was
significantly associated with subsequent VR (Table 1). No
significant correlations were observed in any pair of the baseline
quantitative parameters, except for usRNA and msRNA
(P=0.023, rs=0.51). Among the antiretroviral drugs received by
the patients, only the use of nelfinavir was significantly associated
with VR (P=0.024), confirming earlier reports [9,11]. No
significant association of the presence of drug-resistant HIV-1
strains at baseline and subsequent VR was apparent.
Figure 1 shows levels of HIV-1 prDNA, usRNA, and CD4
+
counts at baseline and at four time points during the eclipse phase
in all patients (Figure 1A), and the failures and successes separately
(Figure 1B). Significant changes from baseline in levels of all
parameters were observed after cART initiation (Figure 1A). The
median (IQR) drop in prDNA level between the baseline and the
first time point on cART was 0.49 (0.40–0.78) log10 (P=0.002),
whereas the corresponding drop in usRNA level was 1.05 (0.90–
1.50) log10 (P,0.001). The difference between the drops in
prDNA and usRNA levels was significant (P=0.002). Subsequent-
ly, we used repeated measures analysis of variance (RM-ANOVA)
to compare the under-therapy levels of HIV-1 prDNA, usRNA,
and CD4
+ count between the patient groups. Baseline values were
excluded from this analysis. No significant differences were
observed between the failures and successes in the under-therapy
level of prDNA and CD4
+ count (figure 1B). Conversely, there was
a statistically significant difference in the level of usRNA under
cART between the patient groups (P=0.0015), the median
usRNA level of failures being 0.43 log10 higher than that of
successes. This difference was established early after the start of
cART and observed throughout the eclipse phase (Figure 1B).
Next, we estimated average longitudinal trends of the
parameters during the eclipse phase by fitting linear mixed models
(Figure 2). Again, baseline values were excluded from this analysis.
Trends observed for prDNA and CD4
+ count were statistically
significant (P=0.006 and P=0.005, respectively), with prDNA
declining on average by 0.12 log10/year, and CD4
+ T cell number
increasing by 68 cells/mm
3 blood/year. Levels of usRNA did not
significantly change over time in all patients (Figure 2A), and the
separate patient groups (Figure 2B). In this analysis, statistically
significant difference in the levels of virological parameters
between failures and successes was again observed only for the
levels of usRNA (P=0.005; Figure 2B).
Based on the observation that higher levels of usRNA are
associated with higher risk of VR, we used the maximal value of
usRNA measured during the eclipse phase to determine a
clinically relevant cutoff value of HIV-1 usRNA in PBMC for
the risk of VR. Area under the receiver operating characteristic
(ROC) curve was 0.800 (95% CI, 0.598–0.929; P=0.0006),
indicating the ability of the maximal level of usRNA under therapy
to correctly predict VR in 80% of random cases, and the cutoff
value of usRNA was 3.43 log10 copies/mg total RNA (,2700 cop-
ies/mg total RNA). As shown by the Kaplan-Meier plot (Figure 3),
whereas the risk of VR remained low (,5%) for maximal under-
therapy values of usRNA smaller than the cutoff value, the risk
increased rapidly for higher values.
Next, we stratified the patients into two groups based on the
determined cutoff value of usRNA. Of the eight patients whose
usRNA level under cART did not reach the cutoff value, only one
experienced VR, whereas VR was observed in 14 out of 18
patients whose maximal usRNA level was higher than the cutoff
value (unadjusted odds ratio (OR), 24.5; 95% CI, 2.3–262.7;
P=0.0033). Subsequently, maximal level of usRNA under cART,
along with other factors associated with the VR in univariate
analyses with significance levels ,0.1 (baseline CD4
+ count, prior
ART experience, use of nelfinavir as PI, use of didanosine as
NRTI), were included in the multivariate logistic regression
analysis. Maximal level of usRNA under cART was independently
predictive of the therapy outcome (adjusted OR for VR (95% CI),
24.4 (1.5–389.5), P=0.024). The only other factor significantly
associated with VR was prior ART experience (adjusted OR (95%
CI), 12.3 (1.1–138.4), P=0.042). Area under curve of the logistic
regression was 0.882 (95% CI, 0.695–0.974, P=0.0004), meaning
that the predictive power of the multivariate model was 88.2%.
Finally, correlation tests were performed between pairs of the
under-therapy levels of the studied parameters (Figure 4A) and
combinations of the baseline and under-therapy levels (Figure 4B).
Figure 4C summarizes the observed correlations. No significant
correlation was observed between the under-therapy levels of
prDNA and usRNA, but levels of usRNA under cART inversely
correlated both with CD4
+ count under therapy (rs=20.56,
P=0.003) and, even more strongly, with baseline CD4
+ count
(rs=20.65, P=0.0003). Of note, no significant correlation was
observed between the baseline and under-therapy levels of
usRNA, whereas baseline and under-therapy levels of prDNA
strongly correlated between each other (rs=0.74, P,0.0001). As
subsequently assessed by Pearson analysis, 40% of the variance of
usRNA level under cART could be explained by the baseline
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8490Figure 1. Levels of virological parameters and CD4
+ counts. Time points on the X axes correspond to the median times from cART initiation of
PBMC samples for every of the sampling time groups (see Methods). Numbers of patients in every sampling time group are indicated on the graphs.
For the upper panels, total numbers of patients are indicated. Median values and interquartile ranges of the studied parameters are indicated. Thin
dotted lines on the upper panels indicate the limit of detection of the modern commercial assays (50 copies/ml). Levels of statistical significance are
depicted on the graphs and signify the following P values: ***, P,0.001; **, 0.001,P,0.01; *, 0.01,P,0.05; ns (not significant), P.0.05. (A) All
patients combined. Parameters were compared between baseline and time on cART-grouped PBMC samples. (B) Patient groups (red, failures; blue,
successes). Parameters were compared between failures and successes. Numbers of failures and successes are indicated by nF and nS, respectively. To
prevent overlap, data sets are nudged between the patient groups.
doi:10.1371/journal.pone.0008490.g001
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+ count, but only 6% of its variance could be explained by the
baseline usRNA level. By contrast, 59% of the variance of prDNA
level under cART could be explained by the baseline prDNA
level.
Due to the low detectability of msRNA in the under-therapy
PBMC samples, we could not assess correlations of this marker
with the other parameters. However, median level of usRNA in
the msRNA
+ under-therapy PBMC samples was 0.48 log10 higher
than usRNA level in the msRNA
2 samples (P=0.034, Mann-
Whitney test), suggesting that the correlation between levels of
usRNA and msRNA, observed at baseline, exists also under
cART. The levels of msRNA in PBMC before the start of cART
were, on average, 1.5 log10 lower than those of usRNA (Table 1).
Interestingly, exactly the same msRNA/usRNA ratio was
observed in the msRNA
+ under-therapy PBMC samples (Table
S1). If this ratio holds for the samples where msRNA was
undetectable, the median level of msRNA in the under-therapy
PBMC samples should theoretically be ,1.9 log10 copies/mg total
RNA, which is below the average limit of detection of our msRNA
assay, explaining the low (16%) detectability of msRNA.
Discussion
The main clinical objective of cART is suppression of HIV-1
plasma viremia to below the lowest existing detection limit of
commercial assays. In most patients on cART, this objective is
achieved, and therefore plasma viremia in these patients cannot be
informative about the subsequent outcome of therapy. Hence,
additional markers have to be identified that are associated with
therapy outcome in patients with fully suppressed plasma viremia.
In this study, we demonstrated that the level of HIV-1 usRNA in
PBMC from such patients is predictive of subsequent VR. To the
best of our knowledge, this is the first report showing that a viral
parameter–measured in a patient on cART during the period of
undetectable plasma viremia–is predictive of the outcome of
therapy. Several reports have indicated the presence of HIV-1
Figure 2. Longitudinal trends of the virological parameters and CD4
+ count during the eclipse phase. The dots represent all the PBMC
samples used in this study. Best-fit lines and their 95% CI are shown by solid and dashed lines, respectively. (A) All patients combined. Levels of
statistical significance of the longitudinal trends are shown on the graphs. (B) Patient groups (red, failures; blue, successes). Levels of statistical
significance of the comparison of the parameters between the patient groups are shown on the graphs.
doi:10.1371/journal.pone.0008490.g002
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mere presence of intracellular viral RNA does not necessarily
imply residual virus replication, and may instead reflect produc-
tion of virus from stable reservoirs without new replication cycles.
In contrast, our observation that patients with higher levels of
usRNA in PBMC were more prone to failing cART might link
higher cellular HIV-1 RNA load in these patients with virus
replication under therapy, which, in turn, resulted in selection of
drug-resistance mutations. Acquired drug-resistance mutations
were indeed observed in all plasma samples sequenced after failure
(data not shown). It remains to be investigated whether drug-
resistance mutations can indeed be detected in PBMC of these
patients during the eclipse phase. Low-level plasma viremia was
recently detected by ultrasensitive assays in most patients on cART
[15,24–26]. Whether this residual viremia reflects ongoing virus
replication despite therapy, or the production of virus from stable
reservoirs without new replication cycles, is controversial
[15,23,26,35,36]. The possible association of the residual plasma
viremia with the outcome of cART and its correlation with the
levels of usRNA in PBMC remain to be studied.
Latently infected resting CD4
+ T cells are considered to be an
extremely stable viral reservoir in patients on suppressive cART,
and a major barrier to HIV-1 eradication [16,21,37–39].
Occasionally, these cells may become reactivated, as a response
to antigens or cytokine induction [21]. Because unfractionated
PBMC were used in our study, we could not discern whether the
HIV-1 usRNA detected in PBMC was derived from resting or
activated CD4
+ T cells, but we assume that the majority of usRNA
was derived from activated CD4
+ T cells, productively infected
with HIV-1. This is supported by the observed differences in
longitudinal trends between prDNA and usRNA after the start of
cART. Whereas levels of prDNA gradually diminished throughout
the whole follow-up period, those of usRNA first sharply declined
after the start of therapy and reached the plateau during the
eclipse phase (Figure 1). These differences can be explained by the
fact that prDNA levels reflect the size of the proviral archive,
whereas levels of usRNA reflect the amounts of productively
infected cells at every moment in time. Similar differences in decay
kinetics between HIV-1 DNA and RNA after the start of ART
have been reported by others [29,32,40,41] and are consistent
with the observations that latently infected cells harboring inactive
HIV proviruses are cleared after the start of therapy much slower
than productively infected cells [19,39,42]. During the eclipse
phase, after the initial drop in the amount of productively infected
cells, very few cells among the total bulk of latently infected cells
would become reactivated at any given moment. However,
because activated CD4
+ T cells can contain up to 4000 copies
of HIV-1 usRNA/cell [43], this small fraction of cells may be
largely ‘‘responsible’’ for the usRNA levels detected in this study.
Then, the observed difference in the usRNA levels between
failures and successes may be shaped by the difference in the
relative amounts of latently infected resting CD4
+ T cells that
become reactivated to the productively infected phenotype and
escape immunological clearance. Importantly, we have observed
that usRNA levels under cART strongly inversely correlated with
baseline CD4
+ counts but did not correlate with either HIV-1
prDNA levels under therapy or baseline levels of HIV-1 usRNA,
prDNA, or plasma RNA (Figure 4). Conversely, a strong
correlation has been observed between baseline and under-
therapy levels of HIV-1 prDNA. Thus, the relative amount of
cells expressing viral RNA at any moment during cART (reflected
in the usRNA level) might be defined, to a large extent, by the
immunological state of the patient before therapy (reflected in the
CD4
+ count), and not simply by the size of viral reservoir (reflected
in the levels of prDNA). Consequently, level of HIV-1 usRNA in
PBMC under cART, which we found to be (i) strongly inversely
associated with baseline CD4
+ count, and (ii) strongly predictive of
subsequent VR, provides a missing link explaining the previously
observed inverse association between the baseline CD4
+ count and
the risk of therapy failure [6,12]. Remarkably, the level of usRNA
under cART was a better predictor of therapy failure than the
CD4
+ count at baseline. Although baseline CD4
+ count could
explain 40% of the variance of usRNA level under cART, other
parameters known to be associated with VR, such as adherence to
cART, may also influence the levels of usRNA.
There are certain limitations to this study. First, our usRNA assay
does not distinguish between genuine intracellular HIV-1 usRNA
and cell-associated virion RNA. However, Fischer et al. [28] have
shown that in patients on cART with plasma viremia suppressed to
,50 copies/ml, extracellular fraction comprised, on average, 0.6%
of total quantified usRNA, which is negligible. Secondly, this study
included patients who started cART, on average, in 1997, and their
therapy regimens would currently be considered suboptimal as a
first-line therapy in the developed world, mainly due to toxicity
issues [44]. While generalization of our findings requires replication
of the results in patients treated with current antiretroviral drugs, we
would like to stress that: (i) antiretroviral drugs received by patients
inthisstudyarestillwidelyused intheresource-limited settings[44],
and a substantial proportion of them is recommended for use as a
first-line therapy in the developing world by the World Health
Organization [45], and (ii) cART regimens used in this study
suppressed plasmaviremia inallofourpatientsto,50 copies/ml,a
clinicallyaccepteddetectionlimitofthemodernultrasensitiveassays
for HIV-1 RNA detection. Furthermore, in PBMC of patients
treated with cART in 2006–2007, levels of usRNA were essentially
similar to those observed in this study (A.O.P. and V.V.L.,
unpublished data).
In summary, our findings demonstrate that the level of HIV-1
unspliced RNA in PBMC is a strong predictive marker for the
outcome of therapy in cART-treated patients. Use of this
quantitative assay in the standard laboratory practice could aid
in monitoring the course of cART and facilitate the early detection
of drug-resistant escape mutants before the actual failure of the
therapy.
Figure 3. The risk of VR according to the maximal usRNA value
during the eclipse phase. Kaplan-Meier plot shows the risk of VR as a
function of maximum usRNA level measured during the eclipse phase.
Small vertical bars show successfully treated patients.
doi:10.1371/journal.pone.0008490.g003
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+ count. Best-fit lines and 95% CI are shown by solid and dashed lines, respectively.
Spearman correlation coefficients (rs) and corresponding P values are indicated within the graphs. Mean values of the quantified under-therapy
parameters per patient (geometric means of log10-transformed values of usRNA and prDNA load and arithmetic means of CD4
+ count) were used.
The units of measurement are log10 copies/10
6 PBMC for prDNA, log10 copies/mg total RNA for usRNA, log10 copies/ml for plasma RNA, and cells/
mm
3 blood for CD4
+ count. (A) Correlations between the under-therapy levels of the studied parameters. (B) Correlations between the baseline and
under-therapy levels. (C) Schematic representation of the correlations shown in panels A and B. Arrows indicate significant correlations, and thickness
of arrows indicates levels of statistical significance: thick arrows, P,0.001; intermediate arrows, 0.001,P,0.01; thin arrows, 0.01,P,0.05.
doi:10.1371/journal.pone.0008490.g004
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Patients and Patient Samples
We have used archival PBMC samples from HIV-1 infected
individuals who were participating in the Amsterdam Cohort
Studies (ACS) on HIV infection and AIDS. The ACS have been
conducted in accordance with the ethical principles set out in the
Declaration of Helsinki, and written informed content has been
obtained prior to sample collection. The study has been approved
by the ACS committee. The ACS have been approved by the
Medical Ethical Committee of the Academic Medical Center.
We have selected 26 HIV-1 infected individuals who received
cART between 1996 and 2002, and have initially responded to
cART by showing undetectable HIV-1 RNA loads in plasma
(,50 copies/ml). cART was defined as at least a triple-therapy
regimen, consisting of two nucleoside reverse transcriptase inhib-
itors (NRTI) and at least one protease inhibitor (PI) or non-
nucleoside reverse transcriptase inhibitor (NNRTI). All patients
were men infected by HIV-1 subtype B strains. Two groups of
patients were selected, matched by median calendar year of cART
initiation: successfully treated patients (n=11) and patients who
experienced VR after initially responding to therapy (failures on
cART; n=15). Individuals treated with cART, in whom HIV-1
plasma viremia dropped to the undetectable levels (,50 copies/ml)
andremained undetectableforthewholeperiodofthetherapy(with
the minimum of one year), were considered to have virological
success. Occasional ‘‘blips’’ (transient episodes of detectable plasma
viremia) of ,500 copies/ml, preceded and followed by measure-
ments of ,50 copies/ml, were allowed. Individuals treated with
cART for at least six months, in whom HIV-1 plasma viremia has
dropped to the undetectable levels after the start of therapy, has
been undetectable for at least three months after that, and
subsequently became detectable (.50 copies/ml in two consecutive
measurements or .500 copies/ml in any measurement), were
considered to experience VR (cART failure). No difference was
observed in the frequency of blips between the patient groups.
Baseline was defined as the date of start of cART. The follow-up
period was calculated from the start of therapy until the date of
first measurement of plasma viremia above the detection limit (for
failures), or until the date of last measurement of plasma viremia
under the current therapy regimen (for successes). Median (IQR;
range) follow-up periods were 2.30 (1.58–3.48; 0.62–6.04) years
for all patients, 2.16 (1.40–2.85; 0.62–3.97) years for failures, and
2.48 (2.11–4.68; 1.32–6.04) years for successes. During the follow-
up period, plasma viremia was monitored at least every four
months, and cellular HIV-1 load was quantified at multiple time
points (Table S1). The numbers of under-therapy PBMC samples
were 24 for failures and 25 for successes. There were no significant
differences between the patient groups in the PBMC sampling
times from the start of therapy (P=0.35). For every PBMC sample
used in this study, concurrent measurements of plasma viremia
and CD4
+ count were available.
Quantitation of HIV-1 Load in PBMC and Plasma Samples
For quantitation of cellular HIV-1 RNA and DNA load, PBMC
were isolated by standard Ficoll-Hypaque density gradient centrifu-
gation and frozen in aliquots in liquid nitrogen. Total cellular nucleic
acids were extracted from PBMC samples (,10
6 PBMC was used for
one extraction) according to the isolation method of Boom et al.[ 4 6 ] ,
eluted in water, and frozen in aliquots at 280uC until further
processing. HIV-1 prDNA and both forms of cellular HIV-1 RNA
( u s R N Aa n dm s R N A )w e r eq u a n t i f i e db ys e m i n e s t e dr e a l - t i m eP C R ,
as described earlier [27]. The eluted cellular DNA was directly
subjected to two rounds of PCR amplification: a limited-cycle pre-
amplification step and a real-time PCR step, using seminested
primers. For RNA quantitation, the eluted RNA samples were first
subjected to DNase treatment (DNA-free kit, Ambion), to remove
HIV-1 prDNA which could interfere with the quantitation, and
subsequently to reverse transcription (RT). For both usRNA and
msRNA assays, two rounds of amplification with seminested primers
were performed on the resultant cDNA. For all assays, no positive
signals have been obtained from the negative controls, as well as from
the –RT controls for RNA assays, which were included in the
quantitation. The amounts of PBMC-derived HIV-1 DNA and RNA
were normalized to total cellular inputs, which were quantified in
separate real-time PCR by using the detection kits for either beta-
actin or ribosomal RNA, respectively(both–Applied Biosystems), and
expressed either as number of copies per 10
6PBMCforprDNA,oras
number of copies per mg total RNA for usRNA and msRNA. The
sensitivity of all three assays was four copies per reaction, which
translated into approximately 40 copies/10
6 PBMC for the prDNA
assay and 100 copies/mg total RNA for RNA assays (actual detection
limits depended on the total cellular inputs of the PBMC samples),
and the linear range was at least five orders of magnitude. The
reproducibility and accuracy of these assays have been demonstrated
earlier [27]. For further validation of the assays, prDNA and usRNA
were quantified in 28 PBMC samples, randomly selected from the
pool of samples from patients under cART, in triplicates (including
independent extraction and RT-PCR). The mean coefficients of
variation, calculated on log10-transformed values, were 5.31% (95%
CI, 4.41–6.31%) for the prDNA assay, and 2.29% (95% CI, 1.35–
5.31%) for the usRNA assay.
Plasma viremia was quantified using commercial ultrasensitive
assays with limits of detection of 40 or 50 copies/ml (Quantiplex
HIV-1 RNA 3.0, Bayer Diagnostics, or M2000RT, Abbott
Molecular), according to manufacturers’ recommendations. For
those patients who were treated with cART before the year 2000
(when ultrasensitive assays for plasma HIV-1 RNA quantitation
were introduced in our laboratory), HIV plasma viremia was
remeasured using the modern ultrasensitive assays.
Determination of Baseline Drug Resistance
To determine the presence of drug-resistant HIV-1 strains at
baseline, we used prDNA extracted from the baseline PBMC
samples as described above. Regions corresponding to the pol gene
of HIV-1 were amplified in the nested PCR with the following
primers: 59Prot I (59-AGGCTAATTTTTTAGGGAAGATCT-
GGCCTTCC-39) and 39ET-21 (59-AGCTGGCTACTATTT-
CTTTTGCTACTACAGGTGG-39) (pol-PCR I), and 59Prot II
(59-TCAGAGCAGACCAGAGCCAACAG-39) and 39RT20 (59-
CTGCCAGTTCTAGCTCTGCTTC-39) (pol-PCR II). PCR
products were sequenced directly using the primers of the pol-
PCR II. The sequenced fragments contained all 99 codons of
protease and the first 284 codons of reverse transcriptase. Analysis
of drug-resistance mutations was carried out using the Geno2-
pheno software (Max-Planck-Institut for Informatics, Saarbru ¨cken,
Germany, available online at http://www.geno2pheno.org/),
which includes the algorithm for the determination of resistance
for every antiretroviral drug individually by using the Z-score
(number of standard deviations above the mean of drug-naı ¨ve
patients) produced by a particular pol genotype.
Sequence Analysis of Real-Time PCR Target Regions and
Control Real-Time PCR: Correction for Mismatch-Related
Quantification Errors
To account for the possible effects of mismatches in the primer
and probe binding regions on the efficiency of real-time PCR,
HIV RNA and cART Failure
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sequence analysis of the target regions of prDNA and usRNA real-
time PCR assays (these two assays are performed with the same set
of seminested real-time PCR primers and probe). Regions
corresponding to the gag gene of HIV-1 and containing the
primer and probe binding sites were amplified in the nested PCR
with the following primers: 59GAG-1 (59-CATGCGAGAGCGT-
CAGTATTAAGCGG-39) and SK39 (59-TTTGGTCCTT-
GTCTTATGTCCAGAATGC-39) (gag-PCR I), and GAG-2I-
SP6 (59-CGATTTAGGTGACACTATAGGGGAAAAAATTC-
GGTTAIGGCC-39) and GAGAE-3-T7 (59-TAATACGACT-
CACTATAGGGACTATTTTATTTAATCCCAGGAT-39) (gag-
PCR II). The PCR products were sequenced directly with the
primers of the gag-PCR II. Subsequently, the effects of
mismatches in the primer and probe binding regions on the
efficiency of real-time PCR were determined by performing the
seminested real-time PCR with the patient-derived PCR ampli-
cons that contained all the primer and probe target sites, as
templates. The concentrations of the template amplicons were
determined spectrophotometrically and equalized by dilution
before real-time PCR. Patient-specific mismatch-related quantifi-
cation errors (MRQE) were calculated as the differences between
the log10-transformed output copy numbers of the individual
mismatched templates and the log10-transformed median output
copy number of the templates without mismatches. The presence
of mismatches did not substantially influence the real-time PCR
quantification, as the difference between the 10% and 90%
percentiles of the MRQE values was 0.26 log10, and the total
range, except for one outlier, was 0.34 log10 (Figure S1). There was
no significant difference in MRQE values between the baseline
samples and the corresponding under-therapy samples (P=0.24,
paired Wilcoxon signed rank test), and between the patient groups
(P=0.17, Mann-Whitney test).
Statistical Analyses
For cellular and plasma HIV-1 load, statistical analyses were
performed on log10-transformed values. All quantified amounts of
prDNA and usRNA in the baseline and under-therapy PBMC
samples were normalized to the individual MRQE values (see
above), and statistical analyses were based on the normalized
values. For the four PBMC samples in which prDNA and/or
usRNA were undetectable, the prDNA and usRNA levels were
left-censored at the corresponding detection limits, normalized to
the MRQE values. For the comparisons of the baseline parameters
between the patient groups, we used Mann-Whitney test for
continuous variables and Fischer’s exact test for discrete variables.
For the comparisons of the levels of usRNA and prDNA and
CD4
+ count in patients on cART, under-therapy PBMC samples
were divided in four groups based on sampling time from cART
initiation: group I, 0.1–0.6 years; group II, 0.7–1.5 years; group
III, 1.9–2.5 years; group IV, 2.9–6.0 years. Any of these groups
did not contain more than one value from any patient. In three
cases, patients were sampled twice in the period corresponding to
the groupings (two cases in group IV and one in group I). In these
cases, mean values per patient were used for the statistical analysis.
The parameters were compared between baseline and time on
cART-grouped PBMC samples by using paired Wilcoxon test and
between failures and successes by using RM-ANOVA. Baseline
values were excluded from the latter analysis. Longitudinal trends
of the studied parameters under cART were estimated by fitting
the linear mixed models, taking into account correlations of
repeated measurements within the individual patients. Subse-
quently, linear mixed models were used to compare the virological
parameters between the patient groups. The cutoff value of
usRNA for the risk of VR was determined by the ROC curve
analysis with therapy outcome as the classification variable and
maximal value of usRNA under therapy as the diagnostic variable.
Correlations of virological parameters and CD4
+ count were
assessed by using Spearman tests. All parameters, except for CD4
+
count under therapy, were normally distributed (P.0.1, D’Agos-
tino & Pearson omnibus normality test), and Pearson r
2 values of
pairwise correlations were calculated for these parameters. RM-
ANOVA was performed by using XLSTAT (http://www.xlstat.
com), logistic regression and ROC curve analysis by using
MedCalc 10.4 (http://www.medcalc.be), and linear mixed model
analysis by using SPSS 16.0 (http://www.spss.com/). All other
statistical tests were performed by using GraphPad Prism 5.01
(http://www.graphpad.com). All statistical tests were two-sided. P
values,0.05 were considered statistically significant.
Supporting Information
Figure S1 Sequences of primer and probe target regions of
seminested real-time PCR assays for usRNA and prDNA
detection.
Found at: doi:10.1371/journal.pone.0008490.s001 (0.07 MB
PDF)
Table S1 HIV-1 load in PBMC and plasma and CD4
+ counts.
Found at: doi:10.1371/journal.pone.0008490.s002 (0.37 MB
PDF)
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